国产利培酮(索乐~)治疗精神分裂症多中心开放性临床研究  

The multi-center and open clinical study in the treatment of schizophrenia by using China-making Risperidone

作　　者：索乐课题协作组 田维才 刘波[1] 涂哲明[1] 蔡德明[1] 邓小鹏[1] 

机构地区：[1]荆州市精神卫生中心,湖北荆州434000

出　　处：《中国民康医学》2007年第23期1011-1012,1015,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:评价国产利培酮(索乐)治疗精神分裂症的疗效和安全性。方法:通过对全国45家精神病医院的962例精神分裂症患者进行多中心,大样本,开放性的为期8周的治疗观察。采用PANSS、CGI、SAS和TESS评定疗效和不良反应。结果:国产利培酮(索乐)对精神分裂症总有效率84.3%,临床总体疗效肯定,不良反应轻,主要是轻度的锥体外系反应,体重增加,因其程度轻,病人基本能耐受。结论:国产利培酮(索乐)对精神分裂症阳性症状及阴性症状均有效,起效快,安全性高,患者对该药依从性好,可作为精神分裂症的首选药物之一。Objective ：The aim of this study was to investigate the efficacy and safety of China - making Risperidone therapy to schizophrenia. Methods：962 of schizophrenia patients from 45 psychopath hospitals were observed for 8 weeks by multi - center and open treatment of China - making Risperidone. PANSS, CGI, SAS ＆ TESS were used to evaluate the efficacy and side effects. Results： The total effectiveness is 84.3%, with a few side effects that mostly the Extrapyramidal and a little weightiness increase. Conclusions： China -making Risperidone is effective and safe therapy in schizophreniag positive and negative symptom, with fast efficacy, high safety and better compliance. It could be used as one of the first - choice medicines in the treatment of Schizophrenia.

关 键 词：精神分裂症 利培酮(索乐) 疗效 安全性 

分 类 号：R971.4[医药卫生—药品] R749.3[医药卫生—药学]